Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−11.2 TWD
−2.14 B TWD
61.41 M TWD
106.39 M
About TANVEX BIOPHARMA INC
Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. It products include filgrastim, trastuzumab, pegfilgrastim, bevacizumab, and pertuzumab injections. The company was founded by Yu Tien Chao on May 8, 2013 and is headquartered in Taipei, Taiwan.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where 6541 is featured.
Frequently Asked Questions
The current price of 6541 is 63.5 TWD — it has increased by 0.16% in the past 24 hours. Watch TANVEX BIOPHARMA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TWSE exchange TANVEX BIOPHARMA INC stocks are traded under the ticker 6541.
6541 stock has risen by 1.64% compared to the previous week, the month change is a −11.29% fall, over the last year TANVEX BIOPHARMA INC has showed a −2.57% decrease.
6541 reached its all-time high on May 4, 2018 with the price of 368.5 TWD, and its all-time low was 35.0 TWD and was reached on May 20, 2024. View more price dynamics on 6541 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
6541 stock is 2.57% volatile and has beta coefficient of 0.54. Track TANVEX BIOPHARMA INC stock price on the chart and check out the list of the most volatile stocks — is TANVEX BIOPHARMA INC there?
Yes, you can track TANVEX BIOPHARMA INC financials in yearly and quarterly reports right on TradingView.
TANVEX BIOPHARMA INC is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
6541 net income for the last quarter is −318.46 M TWD, while the quarter before that showed −366.72 M TWD of net income which accounts for 13.16% change. Track more TANVEX BIOPHARMA INC financial stats to get the full picture.
No, 6541 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TANVEX BIOPHARMA INC EBITDA is −1.27 B TWD, and current EBITDA margin is −2.89 K%. See more stats in TANVEX BIOPHARMA INC financial statements.
Like other stocks, 6541 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TANVEX BIOPHARMA INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TANVEX BIOPHARMA INC technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TANVEX BIOPHARMA INC stock shows the neutral signal. See more of TANVEX BIOPHARMA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.